Margaret Horn - Mar 11, 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Chief Operating Officer
Signature
/s/ Jack Anders, as Attorney-in-fact for Margaret Horn
Stock symbol
RVMD
Transactions as of
Mar 11, 2024
Transactions value $
-$708,837
Form type
4
Date filed
3/13/2024, 04:32 PM
Previous filing
Mar 5, 2024
Next filing
Mar 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $64.4K +15.7K +11.04% $4.09 158K Mar 11, 2024 Direct F1, F2
transaction RVMD Common Stock Sale -$535K -15.7K -9.95% $34.02 142K Mar 11, 2024 Direct F1, F2, F3
transaction RVMD Common Stock Options Exercise $32.5K +7.94K +5.57% $4.09 150K Mar 12, 2024 Direct F1, F2
transaction RVMD Common Stock Sale -$270K -7.94K -5.28% $34.07 142K Mar 12, 2024 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -15.7K -23.04% $0.00 52.6K Mar 11, 2024 Common Stock 15.7K $4.09 Direct F1
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -7.94K -15.1% $0.00 44.6K Mar 12, 2024 Common Stock 7.94K $4.09 Direct F1

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.
F2 Includes 100,013 restricted stock units.
F3 This transaction was executed in multiple trades in prices ranging from $34.00 to $34.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 This transaction was executed in multiple trades in prices ranging from $34.00 to $34.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.